What most patients want to know first

For most people, the immediate questions are cost, fit, and how certain the evidence is. At London Cartilage Clinic, the current published self-pay price for ChondroFiller is £3,000 for 1 box, £5,500 for 2 boxes, and £8,000 for 3 boxes; that package includes the consultation, ultrasound, the product, the injection, and a six-week follow-up.

The clearest public fit is a knee with a focal cartilage defect rather than just any painful arthritic joint. The clinic describes ChondroFiller as best suited to selected patients with persistent local knee cartilage damage that has not fully settled with conservative care, with imaging reviewed and the defect mapped before a treatment plan is agreed.

Payment and evidence both need a measured view. London Cartilage Clinic describes the treatment as self-funded private care, not NHS or routine PMI, although internal MSK guidance says some workflows use CCSD codes W3111 and W8500 and that written pre-authorisation is needed because cover depends on the insurer and the policy. Published knee data are still limited: a 2024 series reported 17 arthroscopic knee cases with improved Lysholm and IKDC scores through 12 months, which is encouraging but not the same as large comparative trial evidence.

What ChondroFiller is actually designed to do

ChondroFiller is not a steroid-style painkiller and it is not a standard lubricant injection. It is a cell-free collagen scaffold — often described clinically as acellular matrix-induced chondrogenesis — placed into a cartilage defect to support the body’s own repair processes rather than simply ease symptoms. The manufacturer says the collagen matrix hardens into a hydrogel in about 3 to 5 minutes after placement.

That behaviour helps explain why candidacy centres on a defined lesion. A scaffold that is positioned within a mapped defect makes more sense for a focal patch of cartilage loss than for diffuse wear spread across the whole knee. This is why imaging review and defect mapping matter: the treatment is aimed at a local structural problem, not broad symptomatic osteoarthritis on its own.

Who may be a candidate and who may not

A clearer way to judge suitability at Harley Street is by the match between symptoms and the scan, not by pain intensity alone. At London Cartilage Clinic, planning is based on examination plus imaging review in a one-hour consultation, because the key question is whether the knee problem can be traced to one repairable area rather than general wear.

• May be suitable: a knee with localised symptoms that repeatedly point to the same spot on MRI or other imaging — for example loading pain or mechanical irritation from a defined cartilage lesion — with ongoing problems after physiotherapy or other non-operative care.
• Less likely to suit: pain that feels diffuse or "all over", stiffness and swelling linked to broader degeneration, or imaging that shows advanced osteoarthritis across the joint rather than one contained defect.

The manufacturer, Meidrix, describes ChondroFiller as filling "lesions, tiny tears and cavities" and stabilising in about 3 to 5 minutes. That helps explain why borderline cases need a clinician-led decision: the size and site of the defect, whether symptoms actually match it, and the wider condition of the knee all matter. A visible defect on a scan may still be the wrong target if the rest of the joint is too worn or the symptom pattern does not fit.

What the published UK price covers

Rather than treating ChondroFiller as one fixed national fee, London Cartilage Clinic on Harley Street prices it by box count. Its current guide tiers are £3,000 for 1 box, £5,500 for 2 boxes and £8,000 for 3 boxes. The clinic also says most defects are treated with 1 box, while larger or multi-compartment defects may need 2 or 3, so the main budget driver is the treatment plan rather than a single standard knee price.

The published package covers more than the implant itself: consultation, ultrasound, the ChondroFiller product, the injection, and a six-week follow-up are included in those figures. The same London Cartilage Clinic page says this box-based pricing applies across joints, which is another reason not to read the numbers as a UK market average for every knee clinic. In practical budgeting terms, the key variable is usually how much product the mapped defect requires, not a separate national tariff for the knee.

CCSD coding and insurance cover

For payment planning, London Cartilage Clinic presents ChondroFiller as a self-funded private treatment, described on its public page as “not NHS or PMI”. Internal MSK guidance dated October 2025 adds a narrower point: some insurer contributions may still be possible in certain cases, using CCSD codes W3111 for cartilage regeneration with collagen scaffold and W8500 for arthroscopy. That is not the same as routine insurer recognition, and the practical takeaway is that any contribution depends on the insurer, the policy wording and the clinic’s billing route.

The useful question, then, is not whether ChondroFiller is “covered” in general, but whether a named insurer will authorise it in writing before treatment is booked. The same October 2025 guidance says approvals are reported most often with Bupa, Aviva and WPA, while also stressing that cover is policy-dependent and never guaranteed. Public checking has a limit here: the CCSD schedule itself requires a login, so open verification of those codes is restricted. Taken together, that leaves a clear but cautious position — usually self-pay at Harley Street, with possible insurer input only after clinic-specific coding and written pre-authorisation are confirmed.

What outcomes can reasonably be expected

Published knee data offer cautious optimism rather than firm prediction. In a 2024 case series, 17 patients treated arthroscopically with ChondroFiller for knee chondral lesions showed significant improvement in Lysholm and IKDC scores at 3, 6 and 12 months. That points to the possibility of worthwhile gains in pain and function over the first year, but it is still a small uncontrolled series, not proof of long-term durability or superiority over every other cartilage option.

The more realistic bottom line is that results depend heavily on context: the shape and size of the knee defect, the surrounding joint environment, and whether the symptoms genuinely match a focal cartilage lesion on imaging. In that sense, expectation-setting is less about a product promise and more about selecting the right lesion and the right plan. Where a knee problem remains localised and the scan shows a defined cartilage defect, specialist review of symptoms and imaging is the step that clarifies whether this scaffold-based approach is a sensible fit; that assessment is available at London Cartilage Clinic on Harley Street via londoncartilage.com.

1. [1] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936